Our Purpose

Serving Science

We are focused on providing premium quality products and a superior cell culture experience for our customers. We understand how important cell culture is to the success of life science research. These cells are what enable the scientific breakthroughs that extend and save lives. Your ability to generate quality data is dependent upon using tested, proven products.

Nucleus Biologics new San Diego office grand opening

A trusted source for precision cell culture solutions that feed scientific breakthrough.

Curing disease starts with science

In a perfect world, all scientific experiments move forward without confounding variables. While perfection isn’t possible, mitigating risk by demanding only the highest quality cell culture products will facilitate scientific breakthroughs. Working together, we can speed up discovery and cure disease by ensuring that our products meet the demanding requirements of those fueling today’s increasingly complex scientific innovations.

At the core of cell science

We are elevating consistency and authenticity in cell culture. We believe we can accomplish this by delivering superior products through a transparent, consistent and proven supply chain that eliminates variability for you, our customers.

“For us to achieve our mission of providing the highest quality cell culture solutions to feed scientific breakthrough we must be unrelenting in the pursuit of innovation of product and process.”

– Chief Executive Officer, David Sheehan

Leadership Team

Nucleus Biologics David Sheehan
David SheehanPresident, CEO, Director

Dave has 25 plus years in the life science industry.   Dave was previously at Volcano Corporation a $1.2 Billion, publicly held, life sciences company that was sold to Philips. Dave held various roles including the COO, EVP Global Operations and General Manager Volcano Japan, and President of several business units.  Prior to Volcano, Dave was the President and CEO of Digirad a medical imaging company he took public in 2004.  Prior to that, Dave worked at Baxter and Haemonetics.  He has extensive experience in life sciences, product development, manufacturing, international markets, acquisitions and integrations, and organization development. Dave earned a BSME with Distinction from WPI and an MBA from The Amos Tuck School at Dartmouth College.

Nucleus Biologics Alyssa Master
Dr. Alyssa MasterHead of Operations

Dr. Alyssa Master has ten years of laboratory research experience including five years as a lab manager prior to joining Nucleus Biologics. As a biomaterials engineer, her area of expertise is in the field of nanoparticle-mediated drug delivery, particularly for the delivery of cancer therapeutics. In graduate school, Alyssa was the recipient of both the Medtronic Fellowship and the NIH Ruth L. Kirschstein Predoctoral Fellowship. During these fellowships, Alyssa developed a novel targeted drug delivery platform for intravenous delivery of photodynamic therapy agents. Following graduate school, Alyssa completed a postdoctoral fellowship in the Department of Pharmacology at the University of Illinois at Chicago Medical School and a postdoctoral fellowship in the Division of Molecular Pharmaceutics at the University of North Carolina at Chapel Hill School of Pharmacy. Alyssa has a PhD in Biomedical Engineering from Case Western Reserve University.

Tim SchofieldSenior Director of Cell Therapy Solutions

Tim Schofield has 20 years of sales and marketing experience in molecular diagnostics, life sciences and pharmaceuticals. Tim began his career as a sales representative with Johnson & Johnson and held positions of increasing responsibility at Prometheus Laboratories, bioTheranostics and NanoString Technologies. Tim has launched over twenty products in both US and Global markets during his career. He has extensive experience in immuno-oncology, oncology, and immune mediated diseases of inflammation such as Crohn’s Disease and celiac disease. He is on the Advisory Board for Beyond Celiac. Tim received his MBA from the Atkinson Graduate School of Management at Willamette University, a bachelor’s degree in Business Administration from Western Washington University and a proficiency certificate in Japanese from Sophia University in Tokyo.

Board of Directors

Neil ReismanChairman of the Board

Neil is a managing director and member of the Tavistock Group Board of Directors. Tavistock Group has investments in more than 200 companies across 11 countries, with investment sectors including real estate, hospitality, restaurants, sports, energy, retail, life sciences, agriculture, and finance. Neil works with various portfolio companies and sits on the board of AACo. Prior to that, he chaired the Investment Committee, managed the office of General Counsel and the office of CFO and previously had executive operational roles at several biotech companies in San Diego. Neil has 30 years of business experience with emphasis on finance, operations, legal, tax, and mergers and acquisitions. Neil received his JD in 1986 from the University of Pennsylvania Law School and his BS in Accountancy in 1983 from the University of Illinois. Neil is also a CPA.

Kieran T. GallahueDirector

Kieran was Chairman of the Board and Chief Executive Officer of CareFusion Corporation from 2011 until March 2015 when it was sold to Becton Dickinson. Previously, Kieran joined ResMed, Inc. in 2003 as President and Chief Operating Officer of the Americas, was promoted to the role of President and Chief Operating Officer of ResMed Global in 2004, and Chief Executive Officer and director in 2008. Kieran also served on the board of Volcano Corporation until 2015. Prior to 2002, he held various marketing, sales and financial positions within Nanogen, Inc., Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company. Kieran currently sits on the board of directors of Edwards Lifesciences and Intersect ENT. Kieran has a bachelor's degree from the Rutgers University College of Agricultural and Biological Sciences and an MBA from Harvard Business School.

Dr. Rodney LappeDirector

Rodney served as the Chief Scientific Officer of CovX Research LLC. Rodney joined CovX in January 2004. From January 2004 to December 2011, he was Group Senior Vice President, Pfizer Worldwide Research and Development at CovX Research LLC. He joined Pfizer with the CovX acquisition in 2008. Rodney has a strong understanding of pharmacology, a clear strategic scientific vision and extensive experience in international drug discovery collaborations. From 2000 to 2002, Rodney served as Vice President for cardiovascular and metabolic diseases at Pharmacia. Prior to joining Pharmacia, he held positions of increasing responsibility with Wyeth Laboratories, Rorer Central Researh, CIBA Geigy Pharmaceuticals and Searle Pharmaceuticals. He has been the Chairman of Mirati Therapeutics, Inc. since July 2013 and its Director since June 27, 2012. He has been a Director of MethylGene Inc., since June 27, 2012. He previously served as a Director of Neuren Pharmaceuticals Ltd.. Rodney received his PhD in Pharmacology from Indiana University and his BA from Blackburn College.

Nucleus Biologics David Sheehan
David SheehanPresident, CEO, Director

Dave has 25 plus years in the life science industry.   Dave was previously at Volcano Corporation a $1.2 Billion, publicly held, life sciences company that was sold to Philips. Dave held various roles including the COO, EVP Global Operations and General Manager Volcano Japan, and President of several business units.  Prior to Volcano, Dave was the President and CEO of Digirad a medical imaging company he took public in 2004.  Prior to that, Dave worked at Baxter and Haemonetics.  He has extensive experience in life sciences, product development, manufacturing, international markets, acquisitions and integrations, and organization development. Dave earned a BSME with Distinction from WPI and an MBA from The Amos Tuck School at Dartmouth College.

Anthony J. AbrahamDirector

Mr. Anthony J. Abraham, BEc, LLB (Accountancy and Law) is currently also a Board Director at Australian Agricultural Company Limited. Mr. Abraham previously served as Chief Executive Officer at Macquarie Group. Mr. Abraham enjoyed 21 years in investment banking with the Macquarie Group. Mr. Abraham was involved in agricultural funds management from 2003 within Macquarie until he departed in 2011. Mr. Abraham has a wealth of experience in investment having played an integral role in Macquarie Group's expansion into Australian agriculture. Mr. Abraham joined Macquarie in 1990 after four years in the tax consulting division of a chartered accounting firm.

Contact us for more information

Subscribe